Journal List > J Korean Ophthalmol Soc > v.49(6) > 1008008

Seong, Seong, Jun, Ki, and Bong: Two Cases of Topiramate-induced Acute Myopia

Abstract

Purpose

We describe 2 cases of bilateral acute myopia associated with topiramate, a drug that has recently been prescribed for epilepsy or weight reduction.

Case summary

A 24-year-old woman and a 25-year-old woman, both previously devoid of ocular problems, visited our hospital with blurry vision after taking topiramate for weight reduction. A thorough medical history review and ocular examinations, including a slit lamp examination, were performed.

Conclusions

Slit-lamp examinations revealed forward displacement of the lens-iris diaphragm, which resulted in myopia and anterior chamber shallowing. Discontinuation of topiramate and the administration of cycloplegic agents successfully resolved the symptoms.

References

1. Ziemann U. Phamacology of TMS. Suppl Clin Neurophysiol. 2003; 56:226–31.
2. Gryder DS, Rogawski MA. Selective antagonism of GluR5 Kainate‐ receptor mediated synaptic currents by topiramate in rat basolateral amygdale neurons. J Neurosci. 2003; 18:7069–74.
3. Kockelmann E, Elger CE, Helmstaedter C. Significant improvement in frontal lobe associated neuropsychological function after withdrawal of topiramate in epilepsy patients. Epilepsy Res. 2003; 54:171–8.
4. Bourgeois BF. Phamacokinetics and pharmacodynamics of topiramate. J Child Neurol. 2000; 15:27–30.
5. Richard D, Ferland J, Lalonde J. . Influence of topiramate in the regulation of energy balance. Nutrition. 2000; 16:961–6.
crossref
6. Richard D, Picard F, Lemieux C. . The effect of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Discord. 2002; 26:344–53.
7. Tatum WO, French JA, Faught E. . Postmarketing experience with topiramate and cognition. Epilepsia. 2001; 42:1134–40.
crossref
8. Privitera M, Fincham R, Penry J. . Topiramate placebo- controlled close-ranging trial in refractory partial epilepsy using 600, 800, and 1000 mg daily dosages. Topiramate YE study Group. Neurology. 1996; 46:1678–83.
9. Banta JT, Hoffman K, Budenz EL. . Presumed topiramate- induced bilateral acute angle‐ closure glaucoma. Am J Ophthalmol. 2001; 132:112–4.
10. Sankar PS, Pasquale LR, Grosskreutz CL. Uveal effusion and secondary angle‐ closure glaucoma associated with topiramate use. Arch Ophthalmol. 2001; 119:1210–1.
11. Thambi L, Kapcala LP, Chambers W. . Topiramate associated secondary angle‐ closure glaucoma: a case series. Arch Ophthalmol. 2002; 120:1108.
12. Rhee DJ, Goldberg MJ, Parrish RK. Bilateral angle‐ closure glaucoma and ciliary body swelling from topiramate. Arch Ophthalmol. 2001; 119:1721–3.
13. Fraunfelder FW, Fraunfelder FT, Keates EU. Topiramate associated acute bilateral secondary angle‐ closure glaucoma. Ophthalmology. 2004; 111:109–11.
14. Jeon C, Kee CW. Topiramate‐ induced Acute Angle‐ Closure Glaucoma. J Korean Ophthalmol Soc. 2005; 46:1944–50.
15. Hook SR, Holladay JT, Prager TC, Goosey JD. Transient myopia induced by sulfonamides. Am J Ophthalmol. 1986; 101:495–6.
crossref
16. Bovino JA, Marcus DF. The mechanism of transient myopia induced by sulfonamide therapy. Am J Ophthalmol. 1982; 94:99–101.
crossref
17. Krieg PH, Schipper I. Drug induced ciliary body oedema:a new theory. Eye. 1996; 10:121–6.
18. Sen HA. O’Halloran HS, Lee W. Topiramate‐ induced acute myopia and retinal striae. Arch Ophthalmol. 2001; 119:775–7.
19. Gubbay SS. The occurrence of drug‐ induced myopia as a transient side effect of topiramate. Epilepsia. 1998; 39:451.
20. Craig JE, Ong TJ, Louis DL, Wells JM. Mechanism of topiramate‐ induced acute‐ onset myopia and angle closure glaucoma. Am J Ophthalmol. 2004; 137:193–5.
21. Medeiros FA, Zhang XY, Bernd AS. . Angle closure glaucoma associated with ciliary body detachment in patients using topiramate. Arch Ophthalmol. 2003; 121:282–5.

Figure 1.
(Case 1) Note shallow anterior chamber (3 corneal thickness deep centrally) at initial presentation. (A) and (B) the right eye; (C) and (D) the left eye.
jkos-49-1033f1.tif
Figure 2.
(Case 1) Her anterior chamber deepened (6 corneal thickness deep centrally) with cycloplegics after cessation of topiramate. (A) and (B) the right eye; (C) and (D) the left eye.
jkos-49-1033f2.tif
Figure 3.
(Case 2) Her fundus photograph suggests no specific finding.
jkos-49-1033f3.tif
Figure 4.
(Case 2) Her OPD scan of the right eye. Note refractive error (-7.50/-0.50×46).
jkos-49-1033f4.tif
Figure 5.
(Case 2) Her OPD scan of the left eye. Note refractive error (-7.50/-0.75×89).
jkos-49-1033f5.tif
Figure 6.
(Case 2) Her refractive error is (-0.25/-0.25×119) with cycloplegics after cessation of topiramate. Right eye.
jkos-49-1033f6.tif
Figure 7.
(Case 2) Her refractive error is (-0.50/-0.25×92) with cycloplegics after cessation of topiramate. Left eye.
jkos-49-1033f7.tif
TOOLS
Similar articles